Search clinical trials for: JNJ-42756493 Tablet

Total 8367 results

Janssen Research & Development, LLC

Completed

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma

Tumor or Lymphoma

United States, France, Spain
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Hepatic Impairment

Germany
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

Neoplasms | Lymphoma | Adenocarcinoma | Esophagogastric Junction

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)

Advanced Solid Tumor

France, United States, Japan, Belgium, United Kingdom, Germany, Korea, Republic of, Poland, Taiwan, China, Italy, Spain, Australia, Brazil, Argentina
Janssen Research & Development, LLC

Completed

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

Healthy

United States
Janssen Scientific Affairs, LLC

Approved for marketing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Advanced Cancers and FGFR Genetic Alterations
M.D. Anderson Cancer Center

Active, not recruiting

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...

United States
Lung Cancer Group Cologne

Terminated

FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)

NSCLC | Lung Cancer | NSCLC Stage IV | Squamous Cell Lung Cancer | Pulmonary Neoplasm

Germany
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Neoplasm

China, Taiwan, Korea, Republic of
Tasly Pharmaceutical Group Co., Ltd

Completed

Study of Jitongning Tablet to Treat Spondyloarthritis

Spondyloarthritis

China
Janssen Pharmaceutical K.K.

Recruiting

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (TAR-210)

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Japan
Janssen Research & Development, LLC

Recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Korea, Republic of, United States, Germany, Spain, Netherlands
Janssen Research & Development, LLC

Completed

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Urothelial Carcinoma

France, United States, Korea, Republic of, Belgium, Poland, Taiwan, Turkey, Russian Federation, Spain, Italy, United Kingdom, Brazil, Belarus
Aragon Pharmaceuticals, Inc.

Completed

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Healthy

United States
Janssen R&D Ireland

Completed

A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants

Healthy Participants

Belgium
Aragon Pharmaceuticals, Inc.

Completed

A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Withdrawn

Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations

Healthy

Belgium
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

Non-Muscle Invasive Bladder Cancer

United States, Israel
Jnana Therapeutics

Recruiting

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Phenylketonuria

United States, Australia
Yiling Pharmaceutical Inc.

Completed

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

Parkinson Disease

China
The National Institutes of Pharmaceutical R&D Co...

Completed

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Idiopathic Pulmonary Fibrosis

United States
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Atridia Pty Ltd.

Completed

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Inflammatory Bowel Disease

Australia
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Actelion

Completed

A Study of Selexipag in Healthy Male Participant

Healthy

Belgium
Harmony Biosciences, LLC

Active, not recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Prader-Willi Syndrome

United States
Paratek Pharmaceuticals Inc

Active, not recruiting

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Mycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary Infection

United States
Dong Wha Pharmaceutical Co. Ltd.

Completed

The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer

Diabetic Kidney Disease

Korea, Republic of
Rigshospitalet, Denmark

Completed

The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.

Hyponatremia | Metabolic Bone Disease

Denmark
Hansoh BioMedical R&D Company

Not yet recruiting

A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

Vasomotor Symptoms

China
Sinew Pharma Inc.

Completed

Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers

Nonalcoholic Steatohepatitis

Taiwan
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Lymphoma, Non-Hodgkin

Denmark, Israel, Spain, Australia
Janssen-Cilag International NV

Completed

A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants

Healthy
Aveiro University

Completed

Table to Tablet (T2T): A Novel Intervention Framework for Children With Speech Sound Disorders

Speech Disorders

Portugal
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants

Healthy

Netherlands
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

Schizophrenia

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States, Israel, Korea, Republic of, Netherlands, Belgium, Spain, Australia, Poland, France, Georgia, Moldova, Republic of, Ukraine

3

Subscribe